Targeted treatment for fatty liver disease using genetic medicine
A Precision Targeted Therapeutics for Nonalcoholic Fatty Liver Disease
This study is testing a new genetic treatment for people with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) who have a specific gene mutation, to see if it can help reduce fat in the liver and improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10832053 on NIH RePORTER |
What this research studies
This research investigates a new approach to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) by using a specialized genetic medicine that targets a specific genetic mutation. The study focuses on developing an allele-specific small interfering RNA (siRNA) that can reduce the harmful effects of a protein associated with the progression of these liver diseases. By targeting the PNPLA3 gene mutation, the research aims to prevent the accumulation of fat in the liver and improve patient outcomes. Patients with this genetic mutation may have a unique response to this treatment, which could lead to significant advancements in managing these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis who carry the PNPLA3 148M allele.
Not a fit: Patients without the PNPLA3 148M allele or those with other forms of liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from fatty liver disease, potentially reversing liver damage and improving overall health.
How similar studies have performed: This approach is novel and has not been extensively tested in previous research, making it a potentially groundbreaking strategy for treating NAFLD/NASH.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Liu, Wanqing — Wayne State University
- Study coordinator: Liu, Wanqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.